GTF2F2: A Potential Drug Target for Neurodevelopmental Disorders

Target Name: GTF2F2

NCBI ID: G2963

GTF2F2

GTF2F2: A Potential Drug Target for Neurodevelopmental Disorders

GTF2F2 (TfiiF-beta), also known as Tf-beta, is a protein that plays a crucial role in the development and maintenance of tissues, particularly neural cells. GTF2F2 is a key regulator of the microtubule network, which is a network of filaments that transports vesicles and proteins within cells. Mutations in GTF2F2 have been linked to a range of neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, and ALS. As a drug target or biomarker, GTF2F2 is a promising target for new therapies aimed at treating these debilitating conditions.

The microtubule network is a complex system that plays a vital role in the mechanical properties of cells, including their flexibility and the transport of vesicles and proteins. GTF2F2 is a key regulator of the microtubule network, and its absence has been linked to the misfolding and dysfunction of microtubules. Microtubules are composed of a protein called tubulin and a protein called tau, which are arranged in a repeating pattern to form a double helix. The interaction between tubulin and tau is critical for the stability and dynamics of the microtubule network.

Mutations in GTF2F2 have been linked to a range of neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, and ALS. These mutations have been shown to disrupt the stability and function of the microtubule network, leading to the misfolding and dysfunction of microtubules. The misfolding of GTF2F2 has been shown to cause the formation of aggregates, which can disrupt the stability and function of the microtubule network.

In addition to its role in the microtubule network, GTF2F2 is also involved in the regulation of the cell cycle. It plays a critical role in the G1 phase of the cell cycle, which is the phase of cell growth and preparation for cell division. During the G1 phase, GTF2F2 regulates the accumulation of chromatin at the center of the cell, which is thought to play a role in the regulation of cell division.

As a drug target or biomarker, GTF2F2 is a promising target for new therapies aimed at treating neurodevelopmental disorders. The misfolding and dysfunction of microtubules, as well as the disruption of the cell cycle, have been linked to a range of neurodevelopmental disorders. Targeting GTF2F2 with small molecules or other therapeutic agents has the potential to disrupt the misfolding and dysfunction of microtubules, potentially leading to the improvement of symptoms in neurodevelopmental disorders.

In conclusion, GTF2F2 is a protein that plays a crucial role in the development and maintenance of tissues, particularly neural cells. Its regulation of the microtubule network and its involvement in the regulation of the cell cycle make it an attractive target for new therapies aimed at treating neurodevelopmental disorders. Further research is needed to fully understand the role of GTF2F2 in the development and progression of neurodevelopmental disorders, as well as the potential therapeutic benefits of targeting this protein.

Protein Name: General Transcription Factor IIF Subunit 2

Functions: TFIIF is a general transcription initiation factor that binds to RNA polymerase II and helps to recruit it to the initiation complex in collaboration with TFIIB

The "GTF2F2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GTF2F2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets